United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/612,285	07/03/2003	Richard Derek Iggo	604-689	5824	
23117	7590 11/06/2006	EXAMINER			
	ANDERHYE, PC	PRIEBE, SCOTT DAVID			
901 NORTH C ARLINGTON	GLEBE ROAD, 11TH F , VA 22203	LOOR	ART UNIT	PAPER NUMBER	
	,		1633		
			DATE MAILED: 11/06/2006		

Please find below and/or attached an Office communication concerning this application or proceeding.

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)
10/612,285	IGGO ET AL.
Examiner	Art Unit
Scott D. Priebe, Ph.D.	1633

Before the Filing of an Appeal Brief	Examiner	Art Unit				
9 • • • • • • • • • • • • • • • • • • •	94					
	Scott D. Priebe, Ph.D.	1633	<u> </u>			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address						
 THE REPLY FILED 24 October 2006 FAILS TO PLACE THIS A 1. The reply was filed after a final rejection, but prior to or or this application, applicant must timely file one of the follow places the application in condition for allowance; (2) a No a Request for Continued Examination (RCE) in compliance time periods: a) The period for reply expiresmonths from the mailing 	n the same day as filing a Notice of wing replies: (1) an amendment, aff otice of Appeal (with appeal fee) in o ce with 37 CFR 1.114. The reply mo	Appeal. To avoid abaidavit, or other evider compliance with 37 C	nce, which FR 41.31; or (3)			
b) The period for reply expires	Advisory Action, or (2) the date set forth ater than SIX MONTHS from the mailing (b). ONLY CHECK BOX (b) WHEN THE 06.07(f). on which the petition under 37 CFR 1.1 tension and the corresponding amount shortened statutory period for reply origing than three months after the mailing date. A brief in compliance with 37 CFR 4	g date of the final rejection of the fee. The appropriate of the fee. The appropriate of the final offite of the final rejection, of the final rejection of the final rejection.	on. ILED WITHIN Ite extension fee iate extension fee ice action; or (2) as even if timely filed,			
appeal. Since a Notice of Appeal has been filed, any repl	y must be filed within the time perio	d set forth in 37 CFR	41.37(a).			
3. The proposed amendment(s) filed after a final rejection, but prior to the date of filing a brief, will <u>not</u> be entered because (a) They raise new issues that would require further consideration and/or search (see NOTE below); (b) They raise the issue of new matter (see NOTE below);						
 (c) ☐ They are not deemed to place the application in being appeal; and/or (d) ☐ They present additional claims without canceling a second content of the present additional claims. 	corresponding number of finally rej		the issues for			
NOTE: <u>See Continuation Sheet</u> . (See 37 CFR 1.1 4 The amendments are not in compliance with 37 CFR 1.1.	• • • • • • • • • • • • • • • • • • • •	mpliant Amendment	(PTOL-324).			
 5. Applicant's reply has overcome the following rejection(s): 6. Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s). 						
7. For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is protected. The status of the claim(s) is (or will be) as follows: Claim(s) allowed:	☑ will not be entered, or b) ☐ wil vided below or appended.	I be entered and an e	explanation of			
Claim(s) objected to: Claim(s) rejected: 1-11,21-23 and 25. Claim(s) withdrawn from consideration:						
 AFFIDAVIT OR OTHER EVIDENCE 8. The affidavit or other evidence filed after a final action, but because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e). 	t before or on the date of filing a No d sufficient reasons why the affidav	otice of Appeal will <u>no</u> it or other evidence is	t be entered a necessary and			
9. The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to o showing a good and sufficient reasons why it is necessary	overcome <u>all</u> rejections under appear y and was not earlier presented. So	al and/or appellant fai ee 37 CFR 41.33(d)(1	ls to provide a 1).			
10. ☐ The affidavit or other evidence is entered. An explanation REQUEST FOR RECONSIDERATION/OTHER		-				
11. The request for reconsideration has been considered bu See Continuation Sheet.		condition for allowar	nce because:			
 12. ☐ Note the attached Information Disclosure Statement(s). 13. ☐ Other: See Continuation Sheet. 	(PTO/SB/08) Paper No(s)	Swott D. Pri	h			
. ·		Scott D. Priebe, Ph Primary Examiner Art Unit: 1633	.D.			

Continuation of 3. NOTE: Proposed claim 1 raises new issues under 35 USC 112, 2nd para. The proposed limitation that the binding sites are "inserted as substitutions for all or part of the wild type E1A transcription factor binding site" is indefinite, E1A is a transcription factor, but it does not bind DNA. If "the wild type E1A transcription factor binding site" was intended to mean "the" transcription factor binding site upstream of E1A, then the limitation lacks antecedent basis, and as shown in Fig. 1A there are multiple such binding sites upstream of the E1A transcribed region in the E1A minimal promoter, E1A enhancer, and 5' ITR. Also, additional limitations have been added without proper punctuation (lines 15-17), and the previous improper punctivation is not corrected. With the proposed amendments to claim 1, claim 4 would be either new matter, i.e. a second packaging signal, or an improper dependent claim since proposed claim 1 already requires relocation of the packaging signal to a specific location, rather than the general location recited in claim 4, and as a result claim 4 would be indefinite.

Continuation of 11. does NOT place the application in condition for allowance because: Most of the arguments are based upon the proposed amendment. Since the amendment has not been entered, these arguments are moot. With respect to the rejection over Iggo, Appellant argues that Iggo limits the early genes whose promoter may be altered to those of the E2 region, arguing that "mechanistically directly involved in viral construct nucleic acid replication" excludes E1A. Iggo, page 8, lines 3-8, teaches that the region whose promoter is altered "may be" the region encoding the polymerase, etc. Since expression of the E1A region is required for activation of the genes encoding the polymerase etc., it is mechanistically directly involved in replicating the viral genome. Also, one explicitly described alternative is modification of the E1B promoter alone, or with additional modifications to the E2 or E1A promoters. The instant claims do not exclude modification of both the E1A and E1B promoters, as suggested in Iggo, page 13.

Continuation of 13. Other: Appellant indicates that an amendment of claim 21 was proposed (Reply, page 8), but there is no proposed amendment to claim 21.